



April 15, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Press Release

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed herewith the Press Release titled “*Dr. Lal PathLabs Becomes South Asia’s First Diagnostic Chain to Launch Advanced Test for Amyloidosis*”.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above



Dr. Lal PathLabs Becomes South Asia's First Diagnostic Chain to Launch Advanced Test for Amyloidosis

New Delhi, April 15, 2025: Dr. Lal PathLabs Limited ("DLPL" / "Dr. Lal PathLabs"), a leader in diagnostic healthcare, has introduced **Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry** – a breakthrough test for accurately identifying different types of **Amyloid proteins**. With this launch, DLPL becomes the **first diagnostic chain in South Asia** to offer this highly specialized test.

Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.

Key Highlights:

- **First-of-its-kind in South Asia** – DLPL pioneers this advanced diagnostic solution.
- **Nationwide Availability** – Samples can be collected from **anywhere in India** and sent to National Reference Lab, Rohini, New Delhi for testing.
- **Accurate Diagnosis** – Helps doctors determine the specific type of Amyloid, enabling targeted treatment and better outcomes.
- **Access for Hospitals** – All hospitals can facilitate sample collection for patients and send to Dr Lal PathLabs for testing.

Commenting on the launch, **Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs**, said, *"Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution."*

Adding further, **Dr. Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy**, stated, *"Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India."*

Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).

This innovation reaffirms Dr. Lal PathLabs' commitment to **delivering advanced, accessible, and reliable diagnostic services across India**.

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the Company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2024 the Company has 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.